Secondary Schizophrenia (172 page)

280–
1

aberrant regional recruitment under

Pelizaeus-Merzbacher Disease,
248

task,
61,
63–
4

prepulse inhibition (PPI),
145,
150,

epilepsy,
96

155,
283,
319–
20

Penfield, W.,
24,
370

Huntington’s Disease,
350

presynaptic DA turnover,
7

penicillin,
394

increased regional brain activation

Price, T.,
265,
266

perception and attentional deficit

in acute PCP-related models,

(PAD),
25

152

primary phospholipid syndrome

ketamine-induced by regional

(PAPS),
383

Perception and Attention Deficit

activation,
146–
7

Model,
372

primary schizophrenia

Niemann-Pick Disease type C,

difference from secondary SZ,
9–
11,

Perlman, S.,
335

217–
18

393

psychotic patient with epilepsy,
92

Perot, P.,
24,
370

as idiopathic,
18

receptor occupancy evaluation with

personality disorders,
397

PET,
66–
7

primary/secondary vs. organic/

schizophrenia,
5,
7

functional categorization,
3

personality changes, and brain tumors,

sensitization,
134

266

proline dehydrogenase (PRODH) gene,

tinnitus,
29

318

pes cavus,
332,
333

Wilson’s Disease,
339

pronator drift test,
48–
9

petit mal,
82

Post, R. M.,
120,
132

protein expression studies,
296

PfC relay,
119

postictal hemiparesis,
85

proteolipid (PLP) gene,
248

pharmaceutical kindling,
93,
105–
6

postictal psychosis (PIP),
83–
5, 85t

brief interictal psychosis as distinct

pseudodeficiency (PD),
242

phenacetylurea,
87

from,
88

psilocybin,
148

phencyclidine (PCP),
121,
142–
5

changes in cerebral blood flow,
85

experimental studies on,
142–
4,
145

duration,
83–
4

Psychiatric Research Interview for

and forced normalization,
87

homeostatic mechanisms,
84–
5

Substance and Mental

illicit use,
142

ketamine and,
147

Disorder (PRISM),
122

psychotic symptoms,
142,
143

pathogenetic mechanisms,
84

psychosis, characteristics of,
181t

431

psychotic mood disorder,
117

visual hallucinations and,
27,
121,

Runeberg, J.,
48

psychotomimetic effects of PCP, LSD,

147–
8

Runge, W.,
204

and ecstasy

N-methyl-D-aspartate glutamate

animal studies, of PCP-related

receptor,
151–
2,
153,
154,

models,
149–
55

155–
6

saccadic eye movements, impaired

amphetamine-induced

pulsatile tinnitus,
29

inhibition of,
66

hyperlocomotion model,

pulvino-cortical dissociations,
66

Sachdev, P.,
189,
191–
3

150–
1

Saijo, T.,
234

PCP-related,
151

pyramidal tract integrity,
48

validity of,
150

Salbenblatt, M. J.,
334

behavior/clinical biomarker

quetiapine,
135,
396,
398,
399

Santhouse, A.,
24

change,
152

ketamine,
152

quetiapine fumarate (Seroquel),
277

sarcosine,
155

MK-801,
152,
153

Quitkin, F.,
48

Satel, S. L.,
132

PCP,
152

Sato, M.,
105–
6,
130

drug development,
154–
5

Rabins, P. V.,
199

clozapine and acute ketamine-

Savard, G.,
83,
84

induced model,
154–
5

raclopride-11C,
66–
7

Scarmeas, N.,
209

lamotrigine and ketamine-

rCBF,
146–
7

induced model,
155

Schedule for Affective Disorders and

LY354740,
155

reality distortion,
66

Schizophrenia (SADS),
122

N-acetylaspartylglutamate

receptive prosodic disturbances,
66

Schedules for Clinical Assessment in

peptidase inhibitors,
155

regional interconnectivity studies,
63

Neuropsychiatry (SCAN),

sarcosine,
155

122

GABAergic interneuron deficits,

region of interest (ROI) studies,
6

schizoaffective disorder,
293

153–
4

Reith, J.,
92

and acute psychotic disorder,
381–
2

increased prefrontal glutamate,

and antipsychotic medications,
394

152–
3

restriction fragment length

and genetics of schizophrenia,
293

increased prefrontal neuronal

polymorphisms (RFLPs),

and PCP,
117,
143

firing,
153

290

and Prader Willi Syndrome,
329,

increased regional brain

retrospective diagnosis,
17

330

activation,
152

and prenatal infection,
281

ketamine,
152

Rippon, G. A.,
208

MK-801,
152

risperidone,
396

schizophrenia

paradoxical hyperactivation/

corticosteroids,
399

age of onset,
3

hypoactivation,
152

dementia,
397

brain function alterations in,
5–
6

PCP model of schizophrenia,

Friedrich’s Ataxia,
335

cognitive deficit in,
4–
5,
393

155–
6, 156f
,
157

Huntington’s Disease,
353

cognitive domains affected,
4t

pharmacology of PCP and PCP

multiple sclerosis,
277

course and severity,
4

analogues,
151–
2

parkinsonian symptoms,
398

diagnosis,
393

secondary monoaminergic

seizure disorder,
398

early development model,
8–
9

system disturbances,
154

electrophysiological abnormalities,

Roberts, A. H.,
189

conclusions,
157

5

Ecstasy

Roberts, G. W.,
91,
92

environment risk factors,
8

illicit use of,
148–
9

Robins, E.,
116

genetic risk factors,
8

studies,
149

late development model,
9

human studies,
142–
9

Robinson, R. G.,
199–
200

mood symptoms,
393

Ecstasy,
148–
9

Romberg sway,
53,
333

negative symptoms,
3–
4,
393

ketamine,
145–
7

neural developmental theory of,
309

Ron, M. A.,
192

lysergic acid diethylamide,

pathogenesis of,
8–
9

147–
8

Ropacki, S. A.,
206

positive symptoms,
3,
393

phencyclidine,
142–
5

Rosenbaum, G.,
144

prevalence of,
3

ketamine,
145–
7

as primary psychotic disorder,
3–
9

illicit use of,
145

Rottig, S.,
382

secondary olfactory and gustatory

psychosis and,
145–
6

Rounsaville, B. J.,
132

hallucinations in,
32

studies on,
146–
7

secondary tactile hallucinations in,

rubella,
282

symptoms,
145–
7

34

lysergic acid

Rubella Birth Defects Evaluation

secondary visual hallucinations in,

illicit use of,
147

Project (RBDEP),
282

25

schizophreniform disorder,
117,
258

delusional parasitosis,
34

single photon emission computed

schizotypy,
309,
311–
12

schizophrenia,
34

tomography (SPECT),
7

in substance abuse/withdrawal,
35

aberrant regional recruitment under

Schneider, K.,
289

secondary visual hallucinations (VH),

task,
61,
63–
4

Schor, J. D.,
180

23–
5

epilepsy,
96

functional disconnectivity,
64

Schuckit, M. A.,
129,
131

delirium,
25–
6

neurobiology of,
24–
5

hallucinations,
375

Schultz, S. K.,
131

in neurological disorders,
26–
7

Huntington’s Disease,
350

Niemann-Pick Disease type C,

Schulz, B. W.,
288

localized pathology,
26

neurodegenerative disorders,

217–
18

Schwartz, M.,
383

26–
7

psychotic patient with epilepsy,
92

scopolamine,
27

in normal individuals,
23–
4

Wilson’s Disease,
339

secondary auditory hallucinations

in psychiatric disorders,
25–
6

Slade, P.,
21

(AH),
28–
31

delirium,
25–
6

Slater, E.,
17,
88–
9,
192